Eligible patients received SC-002 at 1 of 7 dose levels during the dose-escalation portion of the study.
Thirty-five enrolled patients received ≥1 dose of SC-002. Twenty-three (66%) patients experienced serious adverse events (AEs), 37% considered related to SC-002. Grade 3/4 AEs occurred in 21 (60%) and 2 (6%) patients; the most common were effusion and hypoalbuminemia. One grade 5 AE occurred in 1 patient. Five (14%) patients achieved a partial response and no patients achieved a complete response.
SC-002 treatment was associated with systemic toxicity and limited efficacy.
符合条件的患者在研究的剂量递增部分期间接受7个剂量水平中的1个的SC-002。
35名入选患者接受了≥1剂SC-002。23例(66%)患者出现严重不良事件(AE),37%被认为与SC-002有关。3/4级不良事件发生在21例(60%)和2例(6%)患者中;最常见的是积液和低蛋白血症。1例患者发生1例5级AE。五名(14%)患者获得了部分反应,没有患者获得了完全反应。
SC-002治疗与全身毒性和有限疗效相关。